3Howarth D, Epstein M, Lan L, et al. Determination of the optimal minimum radioiodine dose in patients with Graves' disease : a clinical outcome study. Eur J Nucl Med, 2001, 28: 1489-1495.
4Sabri O, Zimny M, Schreckenberger M, et al. Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease. Nuklearmedizin, 1998, 37: 83-89.
5Alevizaki CC, Alevizaki-Harhalaki MC, lkkos DG, et al. ^131I treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism, Eur J Nucl Med, 1985. 10: 450-454.
6Khanna CM, Sankar R, Magdum M, et al. Early development of transient hypothyroidism after ^131I therapy for thyrotoxicosis. J Assoc Physicians India, 1998, 46: 268-272.
7Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endoerinol Metab, 1998, 83 : 40-46.
8Khanna CM, Jain SK, galia RP. Thyrotoxicnsis-treatment by ^131I therapy and early prediction of hypothyroidism following this therapy.Assoc Physicians India, 1994, 42: 36-38.
3Bourbeau J, Nanlt D, Dang-Tan T.Self-management and behaviour modification in COPD[J].Patient Educ Couns, 2004,52(3) :271-277.
4Dan YC, Peter F, Schneider R. Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded end point study[J]. Thyroid, 2011, 21(6): 647-648.
5Walter MA, Briel M, Christ-Crain M, et al. Effects of anti- thyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials[J]. BMJ, 2007, 334: 514-516.
6Chen Dan Yun,Schneider Peter F,Zhang Xiang Song,He Zhi Min,Jing Jin,Chen Tang Hua.Striving for euthyroidism in radioiodine therapy of Graves’ disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid : official journal of the American Thyroid Association . 2011
